Drug Profile
Resmetirom - Madrigal Pharmaceuticals
Alternative Names: MGL-3196; Rezdiffra; VIA-3196Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Roche
- Developer Madrigal Pharmaceuticals
- Class Antihyperglycaemics; Antihyperlipidaemics; Chlorinated hydrocarbons; Ethers; Hepatoprotectants; Ketones; Nitriles; Pyridazines; Small molecules; Triazines
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-alcoholic steatohepatitis
- Phase II Hyperlipoproteinaemia type IIa